Technology Listings


64 Results Sort By:
Combination Therapy Using Small Molecule Conjugation to Reovirus for TNBC Treatment
ApplicationSmall molecule inhibitor doxorubicin hydrochloride (Dox) conjugated to reovirus for targeted combination therapy of triple-negative breast cancer (TNBC).Key BenefitsTargeted treatment that directly infects and kills breast cancer cells.Increased cytopathicity, cytotoxicity and faster induction of cell death than virus alone.Enhanced sele...
Published: 10/11/2019       Inventor(s): Bernardo Mainou, Roxana Rodriguez, Angela Berger
Subunit-Selective Modulator for Treatment of Neurological Disorders
Application Subunit-selective GluN2C and GluN2D positive allosteric modulators of N-methyl-D-aspartic acid receptors (NMDAR) for treatment of neurological disorders. Key Benefits Specifically targets GluN2C/D subunits for positive modulation of NMDAR activity. Higher potency compared to non-selective modulators. Improved drug-like properties...
Published: 8/26/2019       Inventor(s): Matthew Epplin, David Menaldino, Stephen Traynelis, Dennis Liotta
PET Tracer for Parkinson’s Disease Diagnostic
Application Small molecule PET tracer for Lewy bodies in the brain for diagnosing Parkinson’s Disease or other Lewy body related diseases. Key Benefits PET tracer to enable quantification of α-Syn. Improves diagnosis of Parkinson’s disease. Allows for earlier treatment. Market Summary Parkinson’s disease is a neuro...
Published: 8/26/2019       Inventor(s): Keqiang Ye
Beta Blocker Isomers as Angiogenesis Inhibitors
Application β-blocker inactive form of propranolol for treatment of angiogenic disease. Key Benefits Reduced side-effects, such as low blood pressure and low blood sugar. Increased anti-angiogenic activity compared to the active isoform. Market Summary Angiogenesis is the growth of blood vessels from the existing vasculature. While it...
Published: 7/29/2019       Inventor(s): Jack Arbiser
Small Molecule Inhibitors of Mcl-1 as Anti-Cancer Agent
Application Myeloid cell leukemia 1 (Mcl-1) inhibitor to enhance DNA replication stress sensitivity for cancer therapy. Key Benefits Inhibits DNA repair in cancer cells. Used in combination with existing cancer therapy. Market Summary Chemoresistance occurs when cancer cells develop resistance to chemotherapy drugs, and appearance of chemo...
Published: 6/24/2019       Inventor(s): Xingming Deng, Guo Chen, Abu Syed Md Anisuzzaman
Small Molecule Inhibitors of NADPH Oxidase 4 (NOX4) Signaling
ApplicationSmall molecule inhibitors of NOX4 signaling with a wide array of therapeutic potential.Key BenefitsSmall molecule inhibitors of NOX4 signaling.Low cytotoxicity.Market SummaryThe NADPH oxidase 4 (NOX4) has gained considerable and growing attention during the past years because of its potential key involvement in a variety of diseases, som...
Published: 5/13/2019       Inventor(s): Bernard Lassegue, Kathy Griendling, David Brown, Qian Xu, Osman Guner, J. Phillip Bowen, Amol Kulkarni, E. Blake Watkins
Glycolysis Inhibitors as Potential Cancer Therapeutics
ApplicationA new potential anti-cancer agent that inhibits the glycolytic enzyme PGAM1 and thereby tumor growth.Key BenefitsTargets tumor metabolism by inhibiting glycolytic enzyme and turning off tumor metabolism.Inhibition of glycolytic enzyme (PGAM1) by these inhibitors leads to significant reduction in tumor growth.Market SummaryTreating cancer...
Published: 4/23/2019       Inventor(s): Jing Chen, Taro Hitosugi, Sumin Kang
Alexidine and Analogs to Treat Lung Cancer
ApplicationSmall molecule therapeutic specifically targeting invasive cancer cells for treatment of lung cancer.Key BenefitsInhibits cancer cell invasion.Utilizes a novel mechanism of action.Market SummaryLung cancer is the second most prevalent type of cancer, causing more than 150,000 deaths in the United States per year. One of the main barriers...
Published: 4/12/2019       Inventor(s): Adam Marcus, Jessica Konen, Rachel Commander, Jamie Arnst, Thota Ganesh
Liver Receptor Homolog 1 (LRH-1) Agonist for the Treatment of Type 2 Diabetes and Inflammatory Bowel Disease
ApplicationSmall molecule agonist that changes the expression of LRH-1 genes involved with lipid metabolism and inflammation.Key BenefitsLess toxic and more potent molecule compared to known LRH-1 agonists.More soluble compound that improves its pharmacokinetics (PK).Market SummaryLiver receptor homolog 1 (LRH-1) is a nuclear hormone receptor that ...
Published: 3/26/2019       Inventor(s): Eric Ortlund, Suzanne Mays, Nathan Jui, Autumn Flynn, Michael Dugan
PLK1 Inhibitors for the Diagnosis and Treatment of Small Cell Lung Carcinoma (SCLC)
Application Polo Like Kinase 1 (PLK1) inhibitor as a potent treatment strategy for SCLC patients with a specific TP53 mutation. Key Benefits A personalized cell therapy for recurrent SCLC cases. Higher efficiency in TP53 mediated PLK1 inhibition to control carcinoma. PLK1, a predictive biomarker for SCLC diagnosis. Market Summary Lung can...
Published: 12/6/2018       Inventor(s): Taofeek Owonikoko
1 2 3 4 5 6 7